GURUFOCUS.COM » STOCK LIST » USA » NAS » Illumina Inc (NAS:ILMN) » Definitions » Deferred Tax
Switch to:

Illumina (NAS:ILMN) Deferred Tax

: $47 Mil (TTM As of Jun. 2023)
View and export this data going back to 2000. Start your Free Trial

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Illumina's change in deferred tax for the three months ended in Jun. 2023 was $53 Mil. Its change in deferred tax for the trailing twelve months (TTM) ended in Jun. 2023 was $47 Mil.

Illumina Deferred Tax Historical Data

The historical data trend for Illumina's Deferred Tax can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Illumina Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Deferred Tax
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -18.00 11.00 117.00 -76.00 -23.00

Illumina Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Deferred Tax Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13.00 -6.00 17.00 -17.00 53.00

Illumina Deferred Tax Calculation

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Deferred Tax for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $47 Mil.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Illumina Deferred Tax Related Terms

Thank you for viewing the detailed overview of Illumina's Deferred Tax provided by GuruFocus.com. Please click on the following links to see related term pages.

Illumina (NAS:ILMN) Business Description

Illumina logo
Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Illumina Inc (NAS:ILMN) » Definitions » Deferred Tax
Comparable Companies
NAS:ICLR NYSE:LH NYSE:MTD NYSE:WAT NYSE:DGX NYSE:RVTY NAS:EXAS NYSE:CRL NYSE:A NYSE:QGEN NYSE:TMO NYSE:DHR NYSE:IQV NAS:IDXX XSWX:LONN SHSE:603259 XPAR:BIM XPAR:ERF ASX:SHL NAS:MEDP
Traded in Other Exchanges
ILMN:Mexico ILU:Germany I1LM34:Brazil ILMN:Austria
Address
5200 Illumina Way, San Diego, CA, USA, 92122
Website
https://www.illumina.com
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Executives
Steven Barnard officer: SVP, Chief Technology Officer 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Stephen P Macmillan director 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Scott B. Ullem director C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92614
Andrew Teno director C/O FIR TREE INC., 55 WEST 46TH STREET, 29TH FLOOR, NEW YORK NY 10036
Scott D Ericksen officer: VP, Chief Accounting Officer 5200 ILLUMINA WAY, SAN DIEGO CA 92122
John Edward Frank officer: Chief Public Affairs Officer 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Carissa Rollins officer: SVP, Chief Information Officer 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Kevin Carl Pegels officer: Chief of Global Operations 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Jose Torres officer: VP, Chief Accounting Officer 1300 W. 120TH AVENUE, WESTMINSTER CO 80234
Kathryne Gambrell Reeves officer: SVP, Chief Marketing Officer 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Alexander Aravanis officer: SVP, Chief Technology Officer 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Scott Gottlieb director MOLECULAR INSIGHT PHARMACEUTICALS, 160 SECOND STREET, CAMBRIDGE MA 02142
Susan H Tousi officer: SVP Product Development 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Phillip G. Febbo officer: SVP Chief Medical Officer C/O GENOMIC HEALTH, INC., 301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Joydeep Goswami officer: SVP Corp Business Development SUMITOMO FUDOSAN MITA TWIN BLDG, EAST WING 4-2-8 SHIBAURA MINATO-KU, TOKYO M0 1080023